Management expanded margins by 300bps yet offered a €1.4B sales guidance spread for 2025.
Thesis: Merck is a derivative play on TSMC's CapEx without the pricing power. The 300bps margin expansion in Electronics is driven by volume leverage on fixed costs, not pricing. While the Life Science recovery is genuine, the 'general market inflection' in semiconductors is a hope trade. They are a material supplier in a constrained world where the foundry captures all the rent.
Verdict: AVOID — Conviction: MEDIUM
Catalyst: Q2 earnings when the predicted H2 'general market inflection' in semiconductors likely gets pushed to 2026.
Key Risk: A faster-than-expected recovery in automotive and industrial chips could drive legacy volume leverage higher than modeled.
The Tell: CFO admitting 'the stronger the sales, even if you have good order intake, that ratio [book-to-bill] can come down.' Pre-emptively explaining away a future drop in the key demand metric.
Friction Level: MODERATE_FRICTION — Bull sees structural AI growth separating from the cycle; Bear sees a volume-taker dependent on TSMC with a wide guidance range masking uncertainty.
Report not found
The report data is no longer available. Please return to the archive.